Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY4101174 · 1 trial · 14 indications
Number of participants with dose-limiting toxicities (DLTs)
Number of participants with DLTs
ORR per investigator assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1)
| Arm | Type | Description |
|---|---|---|
| LY4101174 (Dose-escalation, Cohort A1) | EXPERIMENTAL | Escalating doses of LY4101174 administered intravenously (IV). |
| LY4101174 (Dose-optimization, Cohort A2) | EXPERIMENTAL | Comparing 2 or more doses (evaluated during dose escalation) of LY4101174 administered IV. |
| LY4101174 (Dose-expansion, Cohort B1, B2, C1-C5) | EXPERIMENTAL | LY4101174 administered IV. |
| Name | Type | Description |
|---|---|---|
| LY4101174 | DRUG | Intravenous |
Inclusion Criteria: * Have one of the following solid tumor cancers: * Cohort A1: urothelial carcinoma, triple negative breast cancer, non-small cell lung cancer, esophageal cancer, pancreatic cancer, ovarian cancer, cervical cancer (squamous cell carcinoma), head and neck squamous cell carcinom...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
LY4101174 is an investigational small molecule being studied for the treatment of recurrent, advanced or metastatic solid tumors, including urinary bladder neoplasm, triple negative breast cancer, non-small cell lung cancer, esophageal cancer, pancreatic cancer, ovarian cancer, cervical cancer, head and neck squamous cell carcinoma, prostate cancer, renal pelvis cancer, and bladder cancer.
LY4101174 targets Nectin-4, a protein involved in cell adhesion that is expressed on the surface of certain tumor cells. By targeting Nectin-4, the drug is designed to interfere with tumor growth and survival in various solid tumor types.
LY4101174 is being developed by Eli Lilly and Company, a pharmaceutical company listed on the New York Stock Exchange under the ticker symbol LLY.
LY4101174 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is currently being evaluated in an active clinical trial for safety and preliminary efficacy in patients with advanced solid tumors.
LY4101174 is being studied in a Phase 1 clinical trial with the identifier NCT06238479. The trial, titled 'A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors,' is active but not recruiting and has an estimated enrollment of 490 participants across multiple countries including the United States, Australia, Belgium, China, France, Japan, and Spain.
LY4101174 is a unique investigational compound and no alternative names have been reported for it. It is distinct from other Nectin-4 targeting agents, such as enfortumab vedotin, which is an antibody-drug conjugate, whereas LY4101174 is a small molecule.